AXSM Live signaler | Maksimer profitt med Getagraph.com

SELG 1664 min ago

@ $75.22

Utstedt: 3 mai 2024 @ 21:47

Avkastning: -0.56%

Forrige signal: mai 3 - 19:22

Forrige signal: Kjøp

Avkastning: 0.98 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):
Our systems believe the stock currently is undervalued by 0.03% compare to its pairs and should correct upwards.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States...

Stats
Dagens volum	760 943
Gjennomsnittsvolum	720 716
Markedsverdi	3.54B
EPS	$0 ( 2024-02-20 )
Neste inntjeningsdato	( $-1.200 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-14.19
ATR14	$1.960 (2.62%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Jacobson Mark L.	Buy	24 662	Common Stock
2024-04-01	Jacobson Mark L.	Sell	24 662	Stock Option (Right to Buy)
2024-04-01	Jacobson Mark L.	Sell	24 662	Common Stock
2024-03-14	Jeffs Roger	Buy	16 976	Common Stock
2024-03-14	Jeffs Roger	Buy	13 000	Common Stock

INSIDER POWER
55.22
Last 99 transactions
Buy: 2 269 939 \| Sell: 680 650

Korrelasjon (AI algo v.1.1b): Undervalued: 0.03% $74.83 paired level. (Algoen sporer endringene til de mest korrelerte aksjene i sanntid og gir umiddelbar oppdatering)

Volum Korrelasjon

Lang: -0.27 (neutral)

Kort: -0.61 (weak negative)

Signal:(57) Neutral

Axsome Therapeutics Inc Korrelasjon

10 Mest positive korrelasjoner
MMAC	0.888
AMGN	0.885
BOCH	0.879
PDCO	0.878
MIRM	0.876
RNEM	0.87
BATRA	0.869
SINO	0.866
BATRK	0.86
VIRI	0.858

10 Mest negative korrelasjoner
APOP	-0.937
TDAC	-0.893
MAGS	-0.891
CMLF	-0.868
BHTG	-0.861
VTRU	-0.848
GAINL	-0.847
TRIT	-0.845
RMRM	-0.843
XOG	-0.842

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Axsome Therapeutics Inc Korrelasjon - Valuta/Råvare

-0.48
( neutral )

-0.31
( neutral )

0.00
( neutral )

-0.37
( neutral )

-0.01
( neutral )

0.12
( neutral )

Axsome Therapeutics Inc Økonomi

Annual	2023
Omsetning:	$270.60M
Bruttogevinst:	$237.70M (87.84 %)
EPS:	$-5.27

FY	2023
Omsetning:	$270.60M
Bruttogevinst:	$237.70M (87.84 %)
EPS:	$-5.27

FY	2022
Omsetning:	$50.04M
Bruttogevinst:	$44.84M (89.61 %)
EPS:	$-4.86

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-3.47

Financial Reports:

No articles found.

Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Sanntidsoppdatering for Axsome Therapeutics Inc [AXSM]

Upcoming Earnings Alert